Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01900236 · ClinicalTrials.gov registry record · NA
Integrating ENGagement and Adherence Goals Upon Entry iENGAGE to Control HIV
A NA study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- NA
- Development phase
- 371
- Enrollment target
NCT01900236: Completed NA study, sponsored by University of Alabama at Birmingham.
NCT01900236 is a NA study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 371 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01900236, a NA study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- NA
- Development phase
- 371 participants
- Enrollment target
Study Summary
iENGAGE is a 4 session, in-clinic behavioral intervention that is delivered to new clinic patients during the first year of HIV care on a flexible delivery schedule, with intervention visits scheduled to coincide with HIV medical care visits. Interventionists from each participating collaborating site will be trained centrally to implement the iENGAGE protocol. Following study enrollment and baseline assessment, participants will be randomized to treatment as usual and intervention groups. For intervention-arm participants, each iENGAGE intervention session includes: interventionist-delivered educational content for managing HIV medical care appointment-keeping and information sessions for learning to manage HIV medications. The intervention will have a tailored, interactive agenda for each of the 4 sessions based on behavioral motivational interviewing (MI) techniques. The goal of this intervention is for the participant to establish early behaviors that help him/her to arrive at scheduled medical appointments and learn to take medications as prescribed during the initial year of HIV care in order to improve overall health.
Primary Outcome
VL suppression is defined as \<200 copies/ml of blood
Interventions
- BEHAVIORAL Based on behavioral motivational interviewing (MI) technique
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 371 participants |
| Start Date | 2013-12 |
| Est. Completion | 2018-12 |
| Phase | NA |
What the finished NCT01900236 record still lists
NCT01900236 is an interventional study that assigns participants to a tested intervention. The registered 371 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 1 intervention - of which Based on behavioral motivational interviewing (MI) technique is the first listed.
NCT01900236 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01900236 about?
NCT01900236 is a clinical study titled "Integrating ENGagement and Adherence Goals Upon Entry iENGAGE to Control HIV". iENGAGE is a 4 session, in-clinic behavioral intervention that is delivered to new clinic patients during the first year of HIV care on a flexible delivery schedule, with intervention visits scheduled to coincide with HIV medical care visits. Interventionists from each participating collaborating si...
What is the current status of trial NCT01900236?
This trial is currently completed. It is a NA study. The enrollment target is 371 participants. The study started on 2013-12. Estimated completion is 2018-12.
What interventions are being tested in trial NCT01900236?
The interventions under investigation include: Based on behavioral motivational interviewing (MI) technique (BEHAVIORAL).
Who is sponsoring clinical trial NCT01900236?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01900236's enrollment target sits among peer trials
371 281st of 2000 higher than 1,720 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05743673 · 371 participants
SHAPE Test for Preoperative Risk Stratification
- NCT05761847 · 371 participants · NA
Pediatric Medication Therapy Management Trial
- NCT04801589 · 372 participants · Phase 3
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
- NCT04879329 · 372 participants · Phase 2
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia